ABOUT BAPA

Our Mission

Advocate – Educate – Communicate

We strive to organize Bangladeshi-American Pharmacists in a strong and professional platform so they can be more successful in their career and have a fulfilling experience in this country. We work to get the members involved in the socio-political process that determines their future. We hope to motivate everyone to contribute their time and talent to the betterment of the pharmacy profession here at home and in Bangladesh.

Specifically, the purpose of the organization is to foster cooperation and collaboration among Bangladeshi pharmacists residing in North America; to build and maintain relations with other pharmacists’ associations in North America, to support the profession of pharmacy in Bangladesh and in North America; to support and encourage the development of Pharmaceutical Science in Bangladesh; to develop and conduct programs for maintaining and improving the professional standards; to promote welfare of members’ families in case of need; to protect the professional interests of members of the Association.

Our Sponsors

Silver Sponsor

Silver Sponsor

Silver Sponsor

Pharmaceutical News

  • Many countries overusing powerful antibiotics
    on August 6, 2026 at 8:00 am

    Many countries are using too many powerful and inappropriate antibiotics, fuelling antibiotic resistance concerns, while millions lack access to the specific drugs they need. That is according to a major international study of antibiotic use published in The Lancet Public Health. Research led by City St George's, University of London and University of Oxford developed the first global framework that estimates how many and which type of antibiotics each country needs to treat their infections.

  • GLP-1 diabetes drugs linked to increased risk of hair loss
    on August 5, 2026 at 8:00 am

    Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, finds a study published by The BMJ. Although the absolute risk is low, awareness of this potential effect may help to inform shared treatment decisions, say the researchers.

  • Study reveals structure of brain protein and identifies potential drug target for epilepsy research
    on August 4, 2026 at 8:00 am

    Scientists at the Icahn School of Medicine at Mount Sinai have uncovered the first high-resolution structure of NBCn2, a brain protein linked to epilepsy, autism spectrum disorder, and other neurological conditions, and developed the first compounds capable of inhibiting its activity. The findings provide a new framework for studying how altered brain signaling contributes to disease and may help advance future therapeutic research.

  • A secret weapon against superbugs
    on August 3, 2026 at 8:00 am

    Antibiotic resistance has quietly become one of the greatest threats to global healthcare. Each year, drug-resistant bacteria claim lives by rendering once-reliable antibiotics ineffective, turning routine surgeries, cancer treatments, and even common infections into potentially life-threatening events. Scientists around the world are racing to find new ways to stay ahead of these evolving pathogens. The answer may not lie in discovering an entirely new antibiotic, but in reinventing the chemistry behind the ones we already have.

  • Researchers clear two major hurdles for minimally invasive cancer therapy
    on July 31, 2026 at 8:00 am

    In a promising development for cancer treatment, a collaborative research team has overcome two issues that have prevented photo thermal therapy, a much less invasive treatment option than surgery and/or radiation, from becoming more common. Photothermal therapy uses near-infrared laser light to selectively heat and destroy cancer cells. However, when the immune system senses the nanoparticles carrying therapeutic agents it often begins clearing them before they can reach the tumors.